Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.

Shuu-Jiun WangArtemio A RoxasBibiana SaraviaByung-Kun KimDebashish ChowdhuryNaji RiachiMei-Ling Sharon TaiSurat TanprawateTai Tran NgocYi Jing ZhaoDaniel D MikolShaloo PandhiShihua WenSubhayan MondalNadia TenenbaumPeggy Hours-Zesiger

Published in: Cephalalgia : an international journal of headache (2021)

This study of erenumab in patients with episodic migraine from Asia, the Middle East, and Latin America met all primary and secondary endpoints. A consistent numerical benefit was observed with erenumab 140 mg versus erenumab 70 mg across all efficacy endpoints. These findings extend evidence of erenumab's efficacy and safety to patients under-represented in previous trials.ClinicalTrials.gov identifier: NCT03333109.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
clinical trial
study protocol
patient reported outcomes